Contilistat
General
Type : Multitarget, Histamine-Receptor3-H3-Antagonist, Monoamine-oxidase-inhibitor, Piperidine, Indole, HDAC inhibitor, prop-2-yn-1-yl
Chemical_Nomenclature : N1-Hydroxy-N8-((1-(phenylsulfonyl)-5-(3-(piperidin-1-yl)propoxy)-1H-indol-2-yl)methyl)-N8-(prop-2-yn-1-yl)octanediamide
Canonical SMILES : C1(=CC=C2C(=C1)C=C([N]2[S](=O)(=O)C3=CC=CC=C3)CN(CC#C)C(CCCCCCC(NO)=O)=O)OCCCN4CCCCC4
InChI : InChI=1S\/C34H44N4O6S\/c1-2-20-37(34(40)17-10-4-3-9-16-33(39)35-41)27-29-25-28-26-30(44-24-13-23-36-21-11-6-12-22-36)18-19-32(28)38(29)45(42,43)31-14-7-5-8-15-31\/h1,5,7-8,14-15,18-19,25-26,41H,3-4,6,9-13,16-17,20-24,27H2,(H,35,39)\
InChIKey : CHNLUTGNKOZGEG-UHFFFAOYSA-N
Other name(s) : DDI199
Target
References (1)
| Title : Contilistat, a new polyfunctionalized histone deacetylase inhibitor, showing potential capacity to inhibit cholinesterase\/monoamine oxidase enzymes, and modulate histamine 3, sigma 1, 5-HT6 and dopamine 3 receptors for the treatment of cancer and neurodegenerative diseases - Marco-Contelles_2023_Chemrxiv__ |
| Author(s) : Marco-Contelles J , Diez-Iriepa D , Toledano-Pinedo M , Porro A , Almendros P , Rodrguez-Fernndez, MM , Samadi A , Iriepa I , Lopez-Munoz F , Artetxe-Zurutuza A , Matheu A |
| Ref : Chemrxiv , : , 2023 |
| Abstract : |
| PubMedSearch : Marco-Contelles_2023_Chemrxiv__ |
| PubMedID: |